OBJECTIVE: The aim of this study was to assess the consumption of anti-haemophilic drugs by adults and children with severe haemophilia A or B (residual activity of FVIII or FIX < or =2%) and to quantify the average direct medical costs. METHOD: A retrospective multicentre cost-of-illness study from the perspective of French national health insurance system. The costs include only the use of clotting factors. MAIN OUTCOME MEASURE: Consumption was expressed in UI/kg/year and costs in euros/kg/year. RESULTS: From January 1, 2001 to December 31, 2002, data from 81 adults and 30 children with severe haemophilia A (n = 92) or B (n = 19) and included in the "SNH" were collected and analysed. A coagulation factor inhibitor was present in 10 patients (9%). Four of them were high responders. Mean age and body weight were respectively 28 +/- 17 years and 58 +/- 24 kg. Except for one adult patient, all (99%) had outpatient treatment, 44 patients (40%) were hospitalized and treated by recombinant or/and plasma-derived FVIII or FIX or/and rFVIIa. Overall median annual consumption of anti-haemophilic drugs per patient was estimated at 1,333 UI/kg, with a median cost-of-illness of 1,156 euros/kg. Patients with severe haemophilia B consumed more than patients with severe haemophilia A, though not significantly (P = 0.096), with a median of 2,167 vs. 1,100 UI/kg/year and a median cost of 1,760 vs. 917 euros/kg/year (P = 0.13). Children consumed respectively more than adults (P = 0.008), with a median of 3,204 vs. 1,106 UI/kg/year and a median cost of 2,614 vs. 913 euros/kg/year (P = 0.012). The median cost for patients with an inhibitor was 3,291 euros/kg/year, approximately threefold higher than that of patients without an inhibitor (926 euros/kg/year) (P = 0.022). CONCLUSION: It suggests a higher consumption and cost of anti-haemophilic drugs among children when compared to adults. Haemophilia B patients did not consume significantly more than haemophilia A patients, whereas the consumption and cost for patients with or without inhibitors differed significantly.
OBJECTIVE: The aim of this study was to assess the consumption of anti-haemophilic drugs by adults and children with severe haemophilia A or B (residual activity of FVIII or FIX < or =2%) and to quantify the average direct medical costs. METHOD: A retrospective multicentre cost-of-illness study from the perspective of French national health insurance system. The costs include only the use of clotting factors. MAIN OUTCOME MEASURE: Consumption was expressed in UI/kg/year and costs in euros/kg/year. RESULTS: From January 1, 2001 to December 31, 2002, data from 81 adults and 30 children with severe haemophilia A (n = 92) or B (n = 19) and included in the "SNH" were collected and analysed. A coagulation factor inhibitor was present in 10 patients (9%). Four of them were high responders. Mean age and body weight were respectively 28 +/- 17 years and 58 +/- 24 kg. Except for one adult patient, all (99%) had outpatient treatment, 44 patients (40%) were hospitalized and treated by recombinant or/and plasma-derived FVIII or FIX or/and rFVIIa. Overall median annual consumption of anti-haemophilic drugs per patient was estimated at 1,333 UI/kg, with a median cost-of-illness of 1,156 euros/kg. Patients with severe haemophilia B consumed more than patients with severe haemophilia A, though not significantly (P = 0.096), with a median of 2,167 vs. 1,100 UI/kg/year and a median cost of 1,760 vs. 917 euros/kg/year (P = 0.13). Children consumed respectively more than adults (P = 0.008), with a median of 3,204 vs. 1,106 UI/kg/year and a median cost of 2,614 vs. 913 euros/kg/year (P = 0.012). The median cost for patients with an inhibitor was 3,291 euros/kg/year, approximately threefold higher than that of patients without an inhibitor (926 euros/kg/year) (P = 0.022). CONCLUSION: It suggests a higher consumption and cost of anti-haemophilic drugs among children when compared to adults. Haemophilia Bpatients did not consume significantly more than haemophilia Apatients, whereas the consumption and cost for patients with or without inhibitors differed significantly.
Authors: G Auerswald; M von Depka Prondzinski; B Ehlken; W Kreuz; K Kurnik; H Lenk; I Scharrer; W Schramm; R Zimmermann Journal: Haemophilia Date: 2004-09 Impact factor: 4.287
Authors: S Ehrenforth; W Kreuz; I Scharrer; R Linde; M Funk; T Güngör; B Krackhardt; B Kornhuber Journal: Lancet Date: 1992-03-07 Impact factor: 79.321
Authors: P Gautier; M J D'Alche-Gautier; B Coatmelec; A Marques-Verdier; M A Bertrand; J Dieval; A M Berthier Journal: Haemophilia Date: 2002-09 Impact factor: 4.287
Authors: Marianna Cavazza; Yllka Kodra; Patrizio Armeni; Marta De Santis; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Domenica Taruscio; Arrigo Schieppati; Georgi Iskrov; László Gulácsi; Johann Matthias Graf von der Schulenburg; Panos Kanavos; Karine Chevreul; Ulf Persson; Giovanni Fattore Journal: Eur J Health Econ Date: 2016-04-05
Authors: B M Reipert; B Gangadharan; C J Hofbauer; V Berg; H Schweiger; J Bowen; J Blatny; K Fijnvandraat; E S Mullins; J Klintman; C Male; C McGuinn; S L Meeks; V C Radulescu; M V Ragni; M Recht; A D Shapiro; J M Staber; H M Yaish; E Santagostino; D L Brown Journal: Blood Adv Date: 2020-11-24
Authors: Helmut Schweiger; Judit Rejtő; Christoph J Hofbauer; Verena Berg; Peter Allacher; Karl Zwiauer; Clemens Feistritzer; Gerhard Schuster; Cihan Ay; Birgit M Reipert; Ingrid Pabinger Journal: Blood Adv Date: 2022-02-08
Authors: Ana María Jiménez-Cebrián; Patricia Palomo-López; Ricardo Becerro-de-Bengoa Vallejo; Marta Elena Losa-Iglesias; Emmanuel Navarro-Flores; Marta San-Antolín; César Calvo-Lobo; Daniel López-López Journal: Front Psychiatry Date: 2022-07-04 Impact factor: 5.435